TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) Class 1 or 2 or 3~* Scheduled to undergo an elective abdominal surgical procedure under general anesthesia; and:~  * expected to undergo neuromuscular relaxation with rocuronium for~endotracheal intubation; and~* expected to require at least one maintenance dose of rocuronium; and~* expected to require active reversal of neuromuscular blockade; and~* expected to require clinical or subjective neuromuscular monitoring only; and~* expected to recover in the PACU~  * Arm that is accessible for measuring the TOF ratio in the PACU~ * Sexually active female patient of child-bearing potential must agree to use a~medically accepted method of contraception through seven days after receiving~protocol-specified medication.~Exclusion Criteria:~* Anatomical malformations that may lead to difficult intubation~* Neuromuscular disorder(s) that may affect neuromuscular blockade and/or trial assessments~* Dialysis-dependent or has or is suspected of having severe renal insufficiency~* Significant hepatic dysfunction~* Family history of malignant hyperthermia~* Cardiac pacemaker~* Allergy to study treatments or its/their excipients, to opioids / opiates, sugammadex, muscle relaxants or their excipients, or other medication(s) used during general anesthesia~* Toremifene before or within 24 hours of study drug administration~* Scheduled for an overnight stay (or \>12 hours) in PACU~* Expected transfer to an Intensive Care Unit after surgery~* Pregnant, intention to become pregnant between randomization and the Day 30 pregnancy follow-up visit~* Breast-feeding.~* Investigational drug(s) within 30 days of randomization on this study~* Participation in any other clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial~* Participant or family member is among the personnel of the investigational or Sponsor staff directly involved with this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
- Neostigmine/glycopyrrolate (Type: ACTIVE_COMPARATOR): Participants receive neostigmine/glycopyrrolate per usual practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion:~* adult (18+ years)~* current smoker~* current diagnosis of SMI (e.g. schizophrenia, bipolar disorder, major depressive disorder, etc...)~* currently receiving psychiatric rehabilitation services through CBFS and ACT programs at Bay Cove Human Services and Vinfen Corporation~Exclusion:~* intellectual disability (IQ\<70)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment as Usual (TAU) - Cohort 1 (Type: ACTIVE_COMPARATOR): Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention.Cohort 1 (AD-eligible) comprised participants seen in primary care clinics serving ≥3 enrolled participants.
- AD + CHW - Cohort 1 (Type: EXPERIMENTAL): Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. The aim of AD is to help clinicians understand and adopt targeted evidence-based practices.~Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers.
- AD - Cohort 1 (Type: EXPERIMENTAL): Participant in this arm will have Academic Detailing offered to their primary care clinical staff as described above. Participants who are randomized to this condition will not be offered Community Health Worker support.
- CHW - Cohort 2 (Type: EXPERIMENTAL): Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers.
- Treatment as Usual (TAU) - Cohort 2 (Type: ACTIVE_COMPARATOR): Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention. Cohort 2 (AD-ineligible) comprised participants whose primary care clinic served ≤2 enrolled participants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Extensible and Inextensible Lumbosacral Orthoses for Lower Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* chief complaint of lower back pain, with or without lower extremity (LE) symptoms~* 150 subjects will be recruited from patients seeking treatment for lower back pain from spine specialty orthopaedic clinics, family practice physicians, and out-patient physical therapy clinics~Exclusion Criteria:~* Exclusion criteria are:~* previous spinal surgery~* workman's compensation or litigation is involved~* neurological disease or injury~* systemic inflammatory disease~* pulmonary disease which restricts breathing capacity~* current pregnancy~* acute fracture~* tumor or metastatic disease~* infection~* neurological disease~* the presence of pathological reflexes (e.g., Babinski)~* the presence of lower extremity pain upon cervical motion and / or the presence of two or more of the following signs of nerve compression: diminished lower extremity strength in a myotomal distribution, diminished sensation, and / or absence deep tendon reflexes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: OTHER): Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
- Extensible lumbosacral orthoses plus standard of care (Type: EXPERIMENTAL): This group receives a flexible/extensible lumbosacral orthosis, one that is commonly available over the counter
- Inextensible lumbosacral orthoses and standard of care (Type: EXPERIMENTAL): This group receives an inextensible lumbosacral orthoses which leads to 14% increase in trunk stiffness compared to the other conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Decitabine in Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have diagnosed acute myeloid leukemia.~2. Must have a life expectancy of at least 12 weeks.~3. Must sign informed consent.~Exclusion Criteria:~1. Must not have acute promyelocytic leukemia (M3 classification)~2. Must not have any other active systemic malignancies.~3. Must not have inaspirable bone marrow.~4. Must not have received previous chemotherapy (except hydroxyurea) for any myeloid disorder.~5. Must not have chronic respiratory disease that requires continuous oxygen use.~6. Must not have received any experimental drug within 4 weeks before randomization.~7. Must not be a candidate for a bone marrow or stem cell transplant within 12 weeks after randomization.~8. Must not have known HIV.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-80 years old~* American Society of Anesthesiologists(ASA) Ⅰ～III~* patients scheduled for elective hepatectomy~Exclusion Criteria:~• body weight \< 40 kg or \>100 kg; metastases occurring in other distant organs; severe hepatic insufficiency (aspartate aminotransferase or alanine transaminase or bilirubin \> 2.5 times the upper limit of normal), renal impairment (creatinine clearance \< 60 ml/min); cardiac rhythm disorders or systolic heart failure (second-and third-degree heart block, ejection fraction \< 50%); with allergies to any of the trial drugs; inability to comprehend numeric rating scale.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine group (Type: EXPERIMENTAL): at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery.
- placebo group (Type: PLACEBO_COMPARATOR): the same volume of normal saline will be administered during anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of Classical Hodgkin's Lymphoma. Lymphocyte predominant histology will be excluded.~* Primary refractory or relapsed disease proven by biopsy or fine needle aspiration (cytology) of an involved site~* Failure of doxorubicin or nitrogen mustard containing front-line therapy~* 18F-fluorodeoxyglucose-PET scan demonstrating PET avid disease~* Cardiac ejection fraction of greater than 45%, measured since last chemotherapy.~* Adjusted diffusing capacity of greater than 50% on pulmonary function testing, measured since last chemotherapy~* Serum creatinine \< than or = to 1.5 mg/dl; if creatinine \>1.5 mg/dl then the measured 12- or 24-hour creatinine clearance must be \>60 ml/minute.~* ANC\>1000/μl and Platelets\>50,000/μl~* Total bilirubin \< than or = to 2.0 mg/dl in the absence of a history of Gilbert's disease.~* Females of childbearing age must be on an acceptable form of birth control.~* Age between 18 and 72~* HIV I and II negative.~* Patients or their guardians must be capable of providing informed consent.~Exclusion Criteria:~Histology for Lymphocyte predominant subtype Hodgkin's Lymphoma~* Prior treatment with carboplatin, cisplatin, ifosfamide, gemcitabine, or vinorelbine~* Hepatitis B surface antigen positive.~* Known pregnancy or breast-feeding.~* Medical illness unrelated to Hodgkin's Lymphoma, which, in the opinion of the attending physician and/or principal investigator, will preclude administering chemotherapy safely.~* History of any malignancy for which the disease-free interval is \<5 years, excluding curatively treated cutaneous basal cell or squamous cell carcinoma and carcinoma in-situ of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Cytoreductive chemotherapy group 1 (Type: EXPERIMENTAL): Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.
- Cytoreductive chemotherapy group 2 (Type: EXPERIMENTAL): Patients receive ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and etoposide IV over 1 hour twice daily on days 1-3 and 17-19.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Active IgG4-RD~* Compatible pattern of organ involvement consistent with IgG4-RD that cannot be attributed to other causes~* Histopathologically-proven diagnosis of IgG4-RD~* Peripheral blood plasmablast count \>900 cells/mL and/or elevated IgG4-RD levels during screening~* Able and willing to complete the entire study according to the study schedule~* Able and willing to provide written informed consent~Exclusion Criteria:~* History or evidence of a clinically unstable/uncontrolled disorder, condition or disease other than IgG4-RD that, in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion~* Malignancy within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin, or prostate cancer with no recurrence ≥3 years following prostatectomy)~* Presence of recurrent or chronic infections, defined as ≥3 infections requiring antimicrobials over the past 6 months prior to screening~* Active infection requiring hospitalization or treatment with parenteral antimicrobials within the 60 days prior to randomization or oral antimicrobials within the 21 days prior to enrollment~* Patient is taking \>40 mg of prednisone QD~* Prior use of rituximab (or other B cell depleting agents) within 6 months of enrollment. Prior use of any B cell depleting agent greater than 6 months from enrollment is allowed if the CD19+ B cell count is within the normal reference range during screening~* Use of any investigational agent within 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment~* Immunosuppressive agent use within the three months prior to enrollment~* Has received live vaccines within 2 months of enrollment~* Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to end-of-study visit~* Unable or unwilling to partake in the follow-up assessments or required protocol procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- XmAb5871 (Type: EXPERIMENTAL): XmAb5871 administered by IV infusion for up to a total of 12 infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Automatic Testing Feature in New ICDs and CRT-Ds

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have an approved indication, as outlined by American Heart Association/Heart Rhythm Society (AHA/HRS) guidelines, for implantation of an ICD or CRT-D for the treatment of life-threatening ventricular tachyarrhythmia(s) or heart failure, or undergo revision of their ICD or CRT-D system to replace the pulse generator.~* Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluations.~Exclusion Criteria:~* Have a classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 3 months.~* Have had a recent myocardial infarction, unstable angina or cardiac revascularization (percutaneous transluminal coronary angioplasty (PTCA), Stent or Coronary Artery Bypass Graft(CABG)) within 40 days of enrollment.~* Have had a recent cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 3 months of enrollment.~* Are allergic to dexamethasone sodium phosphate (DSP).~* Be currently participating in a clinical investigation that includes an active treatment arm.~* Be pregnant or are planning for pregnancy within 6 months following enrollment.~* Have a life expectancy of less than 6 months.~* Be less than 18 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Promote RF CRT-D (Type: EXPERIMENTAL): Patients with CRT-D device will have the autocapture features of the device tested.
- Current RF ICD (Type: EXPERIMENTAL): Patients with ICD device will have the autocapture features of the device tested.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participant should be healthy on the basis of physical examination, medical history, vital signs, and electrocardiogram and clinical laboratory tests performed at screening~* Have a Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.5 to 30.0 kg/m2, extremes included~* Men and women must agree to use a highly effective method of birth control~Exclusion Criteria:~* Has a positive HIV-1 or HIV-2 test at screening~* Has a Hepatitis A, B or C infection (confirmed by hepatitis A antibody immunoglobulin M (IgM), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody, respectively) at screening~* Has any history of renal insufficiency~* Has a history of significant skin reactions or any history of allergies to drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
- Treatment B (Type: EXPERIMENTAL): Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
- Treatment C (Type: EXPERIMENTAL): Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
- Treatment D (Type: EXPERIMENTAL): Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
- Treatment E (Type: EXPERIMENTAL): Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
- Treatment F (Type: EXPERIMENTAL): Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MedStar Diabetes Pathway Chart Reviews

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 2 Diabetes, A1C equal or higher than 9%, active patient of medstar health provider, english speaking, willing and able to participate in the program~Exclusion Criteria:~* A1C less than 9%, severe illness that precludes participation such severe congestive heart failure or COPD, advanced kidney disease, recent acute illness such as heart attack or stroke in the past 30 days, active cancer, severe mental illness, high dose steroid, other types of diabetes, pregnant or lactating.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cases (Type: None): patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
- Matched controls (Type: None): patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete